Tyrosine kinase inhibitors and multidrug resistance proteins: Interactions and biological consequences

Amalia Azzariti, Letizia Porcelli, Grazia M. Simone, Anna E. Quatrale, Nicola A. Colabufo, Francesco Berardi, Roberto Perrone, Massimo Zucchetti, Maurizio D'Incalci, Jian Ming Xu, Angelo Paradiso

Research output: Contribution to journalArticle

Abstract

Although multidrug resistance (MDR) proteins are known to play a role in drug resistance and modification pharmacodynamic characteristics of certain conventional chemotherapeutics, information about their interactions with tyrosine kinase inhibitors (TKIs) remains fragmentary and somewhat controversial. The chronic administration of TKIs in many clinical situations strongly suggests that any possible interactions with MDR transporters should be studied as a function of time. For example, short periods of exposure to TKIs could provide insights into the nature of the binding to MDR-related proteins, either as substrates or as inhibitors, whereas prolonged exposure to TKIs could provide insights into cellular responses to binding/inhibition of MDR-related proteins. In this report, we provide evidence that suggests that both Gefitinib and Vandetanib may act as transported substrates for Breast Cancer Resistance Protein (BCRP, ABCG2). Conversely, the interaction of Gefitinib and Vandetanib with P-glycoprotein (PgP, MDR1) appeared to be as inhibitors alone. Consistent with this, short periods of exposure (≤24 h) to either Gefitinib or Vandetanib increased the effectiveness of SN-38, the active metabolite of CPT-11. Conversely, prolonged exposure (5 days) decreased SN-38 effectiveness, and was associated with BCRP up-regulation and reduced cell accumulation in S-phase, possibly though reduced intracellular accumulation of SN-38. This report underlines the needs for more detailed characterisation new biologically targeted anticancer drugs, in particular analysing periods of both short and prolonged drug exposure reflecting potentially distinct situations in the clinic in order to optimise future development in combination with established chemotherapeutic approaches.

Original languageEnglish
Pages (from-to)335-346
Number of pages12
JournalCancer Chemotherapy and Pharmacology
Volume65
Issue number2
DOIs
Publication statusPublished - Jan 2010

    Fingerprint

Keywords

  • BCRP
  • Gefitinib
  • P-glycoprotein
  • Resistance
  • Vandetanib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this